Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow

This study has been completed.
Information provided by:
Danish Headache Center Identifier:
First received: September 21, 2006
Last updated: May 29, 2008
Last verified: May 2008
To investigate headache score and accompanying symptoms during and after infusion of PACAP38 i migraine patients

Condition Intervention
Migraine Without Aura
Drug: PACAP38

Study Type: Interventional
Official Title: Basic Scientific Research Investigating PACAP38 Headache Inducing Effects in Migraine Patients

Resource links provided by NLM:

Further study details as provided by Danish Headache Center:

Enrollment: 12
Study Start Date: November 2006
Study Completion Date: November 2007
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: PACAP38
    10 pmol/kg/min given one time
Detailed Description:

To investigate headache score and accompanying symptoms during and after infusion of PACAP38

Changes in regional cerebral blood flow (rCBF) in the area supplied by middle cerebral artery (MCA), blood flow in MCA, diameter of the superficial temporal artery (STA) and radial artery (RA)


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Healthy migraine patient without aura
  • Aged 18-50
  • 50-100 kg
  • Fertile women must use safe contraceptives (IUD, oral contraceptives, surgical sterilisation and long lasting gestagen.

Exclusion Criteria:

  • Tension type headache more than five times/month
  • Other primary headaches
  • Daily medication except contraceptives
  • Drug taken within 4 times the halflife for the specific drug except contraceptives
  • Pregnant or lactating women
  • Exposure to radiation within the last year
  • Headache within the last 48 hours before start of trial
  • Hypertension
  • Hypotension
  • Respiratory or cardiac disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00380263

Dansih Headache Center
Glostrup, Denmark, 2600
Sponsors and Collaborators
Danish Headache Center
Principal Investigator: Henrik Schytz, MD Danish Headache Center
  More Information

Responsible Party: Henrik Schytz/MD, Danish Headache Center Identifier: NCT00380263     History of Changes
Other Study ID Numbers: KA-20060087
Study First Received: September 21, 2006
Last Updated: May 29, 2008

Additional relevant MeSH terms:
Migraine Disorders
Migraine without Aura
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Pituitary Adenylate Cyclase-Activating Polypeptide
Growth Substances
Physiological Effects of Drugs
Vasodilator Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017